MIRUM PHARMACEUTICALS INC (MIRM)

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIRM Makes Notable Cross Below Critical Moving Average

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals appoints Quan as its chief medical officer (NASDAQ:MIRM)

Mirum Pharmaceuticals has named Joanne Quan as its new chief medical officer, who previously held the same position at Nuvig Therapeutics.

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals is Now Oversold (MIRM)

Noteworthy Tuesday Option Activity: MIRM, XP, BTU

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Mirum stock tumbles 20% premarket on failed drug study (NASDAQ:MIRM)

Mirum (MIRM) stock fell 20% in premarket trading Monday after the company reported that a Phase 2 clinical trial for its drug Livmarli failed to meet its primary endpoint.

Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management

Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to...

JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower (NASDAQ:INSM)

JP Morgan said it was bullish on Insmed (INSM), Denali (DNLI), Immunocore (IMCR), Crinetics (CRNX), Mirum (MIRM) and BioCryst (BCRX), rating all as overweight. Read more here.

First Week of July 2024 Options Trading For Mirum Pharmaceuticals (MIRM)

Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference